Provides Additional Protection in Large Markets for Therapeutic Combination in Acclaim-2 Phase 1/2 Clinical Trial Patent Already Granted for Same Combination in U.S. Japan, Australia, Russia and Mexico AUSTIN, Texas, July 5, 2023 /PRNewswire/ — Genprex, Inc. (“Genprex” or the “Company”)…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.